Advances in precision medicine, biomarkers, neuroimaging, and digital health technologies are also supporting the development of more targeted clinical trials in the US. These developments are helping researchers explore innovative therapies while improving patient monitoring and data collection throughout the clinical development process.

Market Overview

According to The Insight Partners, the global neurology clinical trials market was valued at US$6.11 billion in 2025 and is projected to reach US$11.01 billion by 2034, registering a CAGR of 6.76% from 2026 to 2034.The increasing burden of neurological diseases such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke is encouraging greater investment in clinical research. Advances in biomarkers, imaging technologies, genetic research, and digital health tools are also creating new opportunities for more efficient and patient-focused clinical trials. 

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00040115

Market Report Drivers

Increasing Prevalence of Neurological Disorders

One of the major factors supporting the growth of the Neurology Clinical Trials Market is the increasing prevalence of neurological disorders worldwide. Conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke create substantial healthcare needs and continue to drive demand for new treatment options. The aging global population is further increasing the need for therapies targeting age-related neurological conditions. 

Advancements in Neurology Research and Technology

Rapid developments in neuroscience research are contributing to the expansion of neurology clinical trials. Advances in biomarkers, neuroimaging, genetic testing, and molecular research are providing researchers with improved tools for identifying disease mechanisms and evaluating treatment responses.

These technologies can also support patient selection and monitoring during clinical studies, helping researchers develop more targeted approaches for complex neurological disorders. 

Rising Investment in Neurology Drug Development

Increasing investment from pharmaceutical companies, biotechnology companies, governments, and research organizations is supporting the development of new neurological therapies. Growing attention toward conditions with significant unmet medical needs is encouraging companies to expand their clinical development pipelines.

The development of therapies for Alzheimer's disease, Parkinson's disease, epilepsy, stroke, and rare neurological disorders is contributing to continued clinical research activity.

Growing Adoption of Patient-Centric Clinical Trials

Patient-centric approaches are becoming increasingly important in neurology clinical research. Clinical trial sponsors are focusing on improving patient recruitment, engagement, retention, and overall participation experience.

Because neurological disorders can require long-term monitoring, approaches that reduce patient burden and improve convenience may help clinical research organizations and sponsors conduct trials more efficiently. The growing use of decentralized and hybrid trial approaches is also supporting this trend. 

Increasing Use of Digital Health Technologies

Digital technologies are creating new opportunities for neurology clinical trials. Wearable devices, mobile applications, remote monitoring technologies, and digital assessments can facilitate the collection of patient data outside traditional clinical settings.

These technologies may enable more continuous monitoring of neurological symptoms and improve the efficiency of data collection. Their adoption is particularly relevant for clinical studies involving chronic neurological conditions that require long-term observation. 

Growing Focus on Rare Neurological Diseases

The development of treatments for rare and orphan neurological diseases represents another opportunity for the market. Conditions such as Huntington's disease and certain rare genetic neurological disorders often have limited treatment options, encouraging pharmaceutical companies and research institutions to increase clinical research efforts.

Advances in genetic testing and biomarker research may further support the development of targeted therapies for patients with specific neurological conditions. 

Top Players in the Neurology Clinical Trials Market

The global neurology clinical trials market includes pharmaceutical companies, biotechnology companies, contract research organizations, and clinical technology providers. Companies identified by The Insight Partners include

• IQVIA

• PRA Health Sciences

• Charles River Laboratories

• Celerion

• Parexel International

• Covance

• Medidata Solutions

• Pharmaceutical Product Development (PPD)

• Eli Lilly and Co.

• Pfizer Inc

These organizations compete through clinical research services, drug development programs, technology platforms, strategic collaborations, geographic expansion, and investments in innovative clinical trial methodologies.

Market Segmentation

Based on phase, the global Neurology Clinical Trials Market is segmented into:

• Phase I

• Phase II

• Phase III

• Phase IV

Based on study design, the market is categorized into:

• Interventional

• Observational

• Expanded Access

Based on indication, the market includes:

• Epilepsy

• Stroke

• Alzheimer's Disease

• Parkinson's Disease

• Others

The regional analysis covers North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa, with additional country-level analysis. 

Regional Market Outlook

North America represents an important market for neurology clinical trials, supported by a substantial neurological disease burden, advanced research infrastructure, pharmaceutical and biotechnology activity, and investment in drug development. Other market analyses also identify North America as the leading regional market, although market estimates vary by research methodology and reporting period.

Asia Pacific is also creating opportunities for clinical research expansion due to its large patient population, developing healthcare infrastructure, and growing attractiveness as a location for clinical trials. Emerging markets in Asia Pacific and Latin America may provide additional opportunities for sponsors seeking broader patient recruitment and cost-efficient research capabilities. 

Future Outlook

The future of the Neurology Clinical Trials Market is expected to be influenced by advances in precision medicine, biomarker discovery, digital health technologies, and patient-centric trial designs. Increasing collaboration between pharmaceutical companies, biotechnology firms, academic institutions, and clinical research organizations may further accelerate neurological drug development.

The growing use of genetic and biomarker-based approaches could enable researchers to identify patient populations more precisely and evaluate targeted therapies. At the same time, decentralized clinical trials and remote monitoring technologies may help reduce participation barriers and improve data collection.

Related Reports

Creatinine Measurement Market Demand, Share Growth by 2034

Cell Expansion Market Size, Share Growth Forecast Report 2031

About US

The Insight Partners provides comprehensive syndicated and tailored market research services across the healthcare, technology, and industrial sectors. The company delivers market intelligence and strategic insights to help organizations understand emerging trends, identify growth opportunities, and make informed business decisions in rapidly evolving markets.

Contact Us

Contact Person: Ankit Mathur
E-mail:ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876